The biotech industry is entering a new era, where AI is reshaping research, development, manufacturing, and commercial operations. Yet, turning innovation into measurable business value requires more than adopting the latest technology, it demands the right strategy, governance, and trusted partnerships.
Join Nagarro at BioTechX 2026, where our life sciences and healthcare experts will share insights on enterprise AI and engage with industry leaders on the opportunities and challenges shaping the future of biotech.
Catch Nagarro on stage
Build, Buy, or Partner: From Agentic AI Hype to Enterprise Value
Track: Large Language Models
Tuesday, October 6, 2026 | 17:05-17:25 CET
As agentic AI moves from demos to decisions, pharma leaders must decide what to build, what to buy, and where partnerships create the greatest advantage. This panel cuts through the hype to debate ownership, governance, validation, and the real sources of competitive moat in enterprise AI.
Panelists:
Eugen Rosenfeld, CTO in Life Sciences & Healthcare, Nagarro
Stefan Nickels, Director of Global Internal Audit, Daiichi Sankyo Inc
David Stokar, Product Manager, Lean Value Management, Roche
Guillaume Carbonneau, Vice President, Operational Data Insights, Novo Nordisk
Our experts on site
Andrei Doibani
Global Head Public Services and Health, Managing Director, Nagarro
